February 2026 Research Update

This month included one real-world study suggesting that add-on cannabidiol (CBD) treatment can be continued by many families over time and is often linked with fewer seizures, although the study combined many different epilepsy causes rather than focusing only on Angelman syndrome. [1]

In 29 children and adolescents with difficult-to-treat epilepsy (including some with Angelman syndrome), most stayed on CBD through 12 to 24 months, and many had a noticeable drop in seizures by 12 months. Side effects were reported in a minority of patients and were usually described as mild, and some patients stopped CBD because of problems such as lethargy, pneumonia, or worse seizures. [1]

For families affected by Angelman syndrome, this adds one more piece of practical, routine-care evidence that CBD is being used long-term in pediatric epilepsy and that seizure reduction is commonly reported in mixed epilepsy groups. [1]

Because the study did not report results specifically for the Angelman subgroup, it does not answer how well CBD works for seizures in Angelman syndrome compared with other causes of epilepsy. It still helps clarify what kinds of side effects were seen in this clinic population and that medication adjustments often happened alongside CBD, which matters when interpreting how seizure changes were recorded. [1]

A clear trend this month was work on making Angelman syndrome outcomes easier to measure in consistent, meaningful ways, especially for communication and everyday skills. The studies focus less on new treatments and more on improving the tools needed to track change over time, including change that can be captured at home. [2] [3]

One study estimated what amount of change on the ORCA caregiver questionnaire (a measure of communication) might count as a meaningful change, and the suggested thresholds differed depending on which outside score was used as a reference. The authors described these cutoffs as preliminary, but the work lays out a practical approach for deciding when a communication score change is big enough to matter, not just statistically different. [2]

A separate pilot study described building at-home video recording methods to assess functional skills in people with Angelman syndrome, aiming to support remote evaluation. Eleven caregiver-participant pairs completed the pilot, with 96% of planned videos completed and 99% of submitted videos meeting quality standards. The task list was then narrowed to separate sets for ambulatory and minimally ambulatory individuals, although the assessment still needs future validation. [3]

This theme mainly matters for research and future clinical trials, because better measurement can make it clearer whether a therapy is truly helping communication or daily function. It does not point to a new treatment, but it helps clarify how researchers are trying to define changes that are meaningful for families rather than changes that only show up on paper. [2] [3]

What remains uncertain is how stable these communication thresholds will be in different ages and ability levels, and how well remote video methods will perform once tested more broadly. Even with those open questions, this month strengthens the idea that tracking progress in Angelman syndrome is becoming more standardized and more feasible outside of in-person visits. [2] [3]

Preclinical studies this month continued to narrow in on UBE3A, but with a more specific message: different ways of increasing UBE3A may not affect all symptoms equally, and researchers are building better tools to measure UBE3A changes quickly. Together, these papers add detail to how UBE3A might be restored and how progress could be tracked during early testing. [4] [5] [6]

In an Angelman mouse model, boosting the cytoplasmic form of UBE3A rescued most tested behavior differences, but seizure-related measures did not improve in the same way. This points to the possibility that epilepsy features may depend more on loss of UBE3A in the nucleus, at least in this mouse system. [4]

In neuron cultures, reducing UBE3A-ATS (a RNA that normally keeps the paternal UBE3A copy turned off) by targeting SNORD115 increased paternal UBE3A RNA and protein in mouse neurons and in human neuron models from healthy cells. The study also noted concerns that some nearby RNAs could be affected, and it did not yet test patient-derived neurons or whole-animal effects. [5]

A newly developed dual-reporter mouse was designed to preserve normal UBE3A function while adding two different readouts that can be measured in single cells and also tracked in living animals. The goal is to make it easier to screen many potential UBE3A-raising approaches and to see, in real time, whether a therapy is changing UBE3A activity in the brain. [6]

A review article highlighted serotonin receptor 7 (5-HT7R) activation as a possible way to improve synaptic function and learning in Angelman mouse models, and it discussed future testing in human cell models. Because this was a review, it did not add new patient results, but it organized existing preclinical findings around a shared pathway related to brain plasticity. [7]

This theme is early-stage research, but it helps clarify what scientists are learning about which UBE3A changes might matter for different symptoms. The mouse work suggests that improving some behaviors may be possible without automatically improving seizure biology, which is useful context when reading about UBE3A-restoration approaches. [4]

The cell culture findings and the new reporter mouse mainly matter for what could come next, because they support faster testing of approaches aimed at turning on the paternal UBE3A copy and allow more direct measurement of whether UBE3A is changing. What remains uncertain is whether these approaches will be safe and effective in living animals and, later, in people, since that evidence is not yet available from the provided studies. [5] [6]

The 5-HT7R review matters as a research map rather than a new result, by pulling together evidence that a specific brain signaling pathway might be linked to learning-related changes in Angelman models. Whether that pathway can be targeted safely and meaningfully in people is still an open question in the summaries provided. [7]